Sionna Therapeutics today announced that the company’s data will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) to be held November 2-4 in Phoenix, Arizona.
- Poster presentation and Rapid-Fire Poster Talk to feature company's second series of first-in-class NBD1 stabilizers and complementary CFTR modulators - BOSTON, Oct. 18, 2023 /PRNewswire/ -- Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced that the company's data will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) to be held November 2-4 in Phoenix, Arizona. Greg Hurlbut, Ph.D., Co-Founder and Senior Vice President, Discovery Research of Sionna, will present poster number 289, titled, "Beyond SION-638: a novel series of highly potent stabilizers of NBD1 enable full correction of ΔF508-CFTR in a dual combination with Sionna CFTR modulators, providing a path to wild-type function," during a poster session scheduled on Friday, November 3 from 11:40am-12:40pm MST. Dr. Hurlbut will also participate in a Rapid-Fire Poster Talk scheduled on Thursday, November 2 from 8:30-9:10am MST. For more information about NACFC 2023, visit https://www.nacfconference.org/. About Sionna Therapeutics Media Contact Investor Contact
SOURCE Sionna Therapeutics |